Shuji Sato

Summary

Publications

  1. pmc Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers
    Tsutomu Oshima
    Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26 1, Muraokahigashi 2 Chome, Fujisawa, Kanagawa 251 8555, Japan
    Mol Cancer 12:60. 2013
  2. pmc Identification of the cancer cell proliferation and survival functions of proHB-EGF by using an anti-HB-EGF antibody
    Shuji Sato
    Takeda San Francisco, Inc, South San Francisco, California, USA
    PLoS ONE 8:e54509. 2013
  3. pmc A potent anti-HB-EGF monoclonal antibody inhibits cancer cell proliferation and multiple angiogenic activities of HB-EGF
    Shuji Sato
    Takeda San Francisco, Inc, South San Francisco, California, USA
    PLoS ONE 7:e51964. 2012

Collaborators

  • Tsutomu Oshima
  • Yuki Ito
  • Junichi Kato
  • Toshio Kokubo
  • Akira Hori
  • Isamu Tsuji
  • Tomofumi Kurokawa
  • Takahiro Watanabe

Detail Information

Publications3

  1. pmc Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers
    Tsutomu Oshima
    Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26 1, Muraokahigashi 2 Chome, Fujisawa, Kanagawa 251 8555, Japan
    Mol Cancer 12:60. 2013
    ..Nectin-2 is a Ca(2+)-independent cell-cell adhesion molecule that is one of the plasma membrane components of adherens junctions. However, little has been reported about the involvement of Nectin-2 in cancer...
  2. pmc Identification of the cancer cell proliferation and survival functions of proHB-EGF by using an anti-HB-EGF antibody
    Shuji Sato
    Takeda San Francisco, Inc, South San Francisco, California, USA
    PLoS ONE 8:e54509. 2013
    ..In this study, we utilized the anti-HB-EGF monoclonal antibodies Y-142 and Y-073, which have differential specificities toward proHB-EGF, in order to elucidate proHB-EGF functions in cancer cells...
  3. pmc A potent anti-HB-EGF monoclonal antibody inhibits cancer cell proliferation and multiple angiogenic activities of HB-EGF
    Shuji Sato
    Takeda San Francisco, Inc, South San Francisco, California, USA
    PLoS ONE 7:e51964. 2012
    ..Y-142 may have a potential to be developed into a therapeutic agent for the treatment of HB-EGF-dependent cancers...